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Table 1
Variables Total,
N¼77
Regimen 1,
N¼ 60
Regimen 2,
N¼17(%)
P
value
Age, years
median (range)
52(23-69) 52.5(32-69) 52(23-61) 0.40
Female, n (%) 28(36.4) 26(43.3) 2(11.8) 0.017
FISH risk, n(%) 0.55
Low 50(64.9) 40(66.7) 10(58.8)
High 27(35.1) 20(33.3) 7(41.2)
Time from auto
to AHCT, months
median (range)
5.2(3.3-75.2) 5.0(3.0-47.1) 6.3(4.1-75.2) 0.02
Response status
at transplant,n(%)
0.21
CR 23 (29.9) 15 (25.0) 8 (47.1)
PR 47 (61.0) 39 (65.0) 8 (47.1)
SD 7 (9.1) 6 (10.0) 1 (5.9)
CMV reactivation,
n(%)
14 (18.2) 9 (15.0) 5 (29.4) 0.28
Figure 1. Overall survival by conditioning regimen intensity
Figure 2. Progression free survival by FISH risk
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Background: Treatment with TKIs has greatly improved the
outcome of patients with Ph+ALL. However most older pa-
tients are excluded from clinical studies, the curative po-
tential of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) has not been fully analyzed. We examine the
clinical features and transplant outcome of elderly Ph+ALL
patients in the era of TKI.
Methods: We analyzed the data from 30 Ph+ALL patients
aged 50 years or older who had used TKI before allo-HSCT.
Results: The median age was 59 years (range<r>: 50-71);15
patients (50%) were older than 60 years. Subjects comprised
13 males and 17 females. The disease status at allo-HSCT was
complete remission (CR) in 23 patients and non-CR in 7 pa-
tients. Before HSCT, 23 patients received imatinib-based
chemotherapy, and 7 patients received dasatinib-based
chemotherapy. The majority of the donors were HLA-
matched unrelated (n¼16) and related (n¼6), followed by
mismatched unrelated cord blood (n¼7). Median follow-up
for survivors was 247 days (r:16-4,156). The median HCT
comorbidity index score was 1 (r:0-3). Median white blood
cell count at diagnosis was 26.3109/L(r: 4.2-301.9 109/L).
Type of BCR breakpoint was minor in 23 patients (67%).
Graft-versus-host-disease (GVHD) prophylaxis was calci-
neurin inhibitor-based in all patients (CsA:13 patients,
FK506:17). Eleven patients received reduced-intensity con-
ditioning regimens, nineteen patients received myeloa-
blative conditioning regimens. Themedian duration from the
diagnosis to HSCTwas 197 days (95-763). No patient received
TKIs after HSCT.
The probability of overall survival (OS) and disease free
survival (DFS) at 1 year after HSCT were 46.0% and 42.0%,
respectively. These results were not statistically different
compared to the 35 patients aged under 50 years who had
used TKIs before allogeneic HSCT. Multivariate analysis
showed that the factor to inﬂuence OS was disease status (CR
or nonCR) (p¼0.01). Cumulative incidence of nonrelapse
mortality (NRM) was 23.1% at 100 days after HSCT, and 52.0%
at 1 year. The cumulative incidence of acute graft-versus-
host disease <GVHD> (grade II-zW) and chronic GVHD at 1
year were 51.8% and 23.1%. Four patients relapsed after HSCT
with a median of 329 days (r:112-475 days). The estimated
cumulative incidence of relapse at 1 year was 8%. These
outcomes (OS, DFS, NRM, relapse rate) were not signiﬁcantly
different when stratiﬁed by age groups (under vs. older than
60 years old). Increasing age was not associated with in-
creases in acute or chronic GVHD. All of patients aged more
than 60 years had HCT comorbidity index scores of 2.
Eighteen patients died at 139 days (r:16-1,219). The main
cause of death was infection (10 patients).
Conclusion: Allo-HSCT for elderly Ph+ALL patients may be
one of the promising strategy. Allo-HSCT would be effec-
tive option for carefully selected patients aged 60 or older
with Ph+ALL.397
High Doses of Myeloid Progenitor Cells Induce Tolerance
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Bone marrow transplantation has the potential to improve
the outcome of many indications other than cancer, but this
is hampered by the associated complications. Myeloid pro-
genitor cells (MP), which produce a transient engraftment
